| 邢向荣,高 宏,李 康,潘玉真,潘 琳.保肺膏维持治疗中晚期非小细胞肺癌的临床疗效和安全性分析[J].,2021,(4):714-718 |
| 保肺膏维持治疗中晚期非小细胞肺癌的临床疗效和安全性分析 |
| Clinical Observation on the Efficacy and Side Effects of Baofei Ointment in the Treatment of Advanced Non-small Cell Lung Cancer |
| 投稿时间：2020-05-28 修订日期：2020-06-23 |
| DOI：10.13241/j.cnki.pmb.2021.04.024 |
| 中文关键词: 中晚期非小细胞肺癌 维持治疗 保肺膏 免疫功能 毒副反应 |
| 英文关键词: Advanced non-small cell lung cancer Maintenance treatment Baofei ointment Immune function Toxic and side effects |
| 基金项目:辽宁省中医药临床学(专)科能力建设项目-重大疾病中医药综合治疗方案的示范研究(2017A01) |
|
| 摘要点击次数: 681 |
| 全文下载次数: 388 |
| 中文摘要: |
| 摘要 目的：探讨保肺膏维持治疗中晚期非小细胞肺癌(non-small cell lung cancer，NSCLC)的临床疗效和安全性。方法：选择2017年10月至2018年10月在辽宁省肿瘤医院、辽宁中医药大学附属医院、辽宁中医药大学附属二院、沈阳市第二中医院四家医院住院治疗的48例Ⅲ-Ⅳ期NSCLC经一线化疗后进入维持治疗阶段的带瘤患者，根据随机数字表法将其分为两组，对照组给予单药维持化疗，观察组在维持化疗基础上应用保肺膏治疗，治疗后每2个月按照实体瘤的疗效评价RECIST标准进行病灶疗效评价，对比两组的疾病控制率、治疗前后KPS评分、体重、中医症状、免疫功能的变化及毒副反应的发生情况。结果：对照组治疗后2、4、6、8、10、12、14个月的DCR率稍低于观察组(P>0.05)。治疗后，观察组的KPS评分总改善率为91.67 %，体重变化总改善率为93.75 %，均显著高于对照组(62.50 %，66.67 %，P<0.05)。两组治疗后中医症状积分较治疗前明显下降(P＜0.05)，且观察组显著低于对照组(P＜0.05)，观察组总有效率为83.33 %，显著高于对照组(45.83 %，P＜0.05)。两组治疗后患者外周血T淋巴细胞亚群中CD3+、CD4+的细胞计数及CD4+/CD8+值均较治疗前明显升高(P＜0.05)，且观察组上述指标均显著高于对照组(P＜0.05)，T淋巴细胞亚群中CD8+的细胞计数虽较治疗前稍有升高，但组间差异无统计学意义(P＞0.05)。对照组Ⅲ~Ⅳ度粒细胞减少和恶心呕吐发生率高于观察组(P＜0.05)，两组Ⅲ~Ⅳ度血小板减少和腹泻发生率对比无明显统计学差异(P>0.05)。结论：保肺膏能够较好地控制NSCLC发展，改善患者临床症状，提高其免疫力，并且长期服用无明显毒副反应。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the clinical efficacy and effects of Baofei ointment for maintenance treatment of advanced non-small cell lung cancer (NSCLC). Methods: 48 patients with stage III~IV NSCLC who were hospitalized in Liaoning Cancer Hospital, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, and Second Hospital of Shenyang Second Traditional Chinese Hospital from October 2017 to October 2018 patients with tumor who have entered the maintenance treatment stage after first-line chemotherapy were divided into two groups according to the random number table method. Months according to the RECIST criteria for the evaluation of the efficacy of solid tumors to evaluate the effect of the lesions, comparing the disease control rate, KPS score before and after treatment, weight, TCM symptoms, immune function changes and the occurrence of side effects in the two groups. Results: The DCR rate of the control group was slightly lower than that of the observation group at 2, 4, 6, 8, 10, 12, and 14 months after treatment (P>0.05). After treatment, the total improvement rate of KPS score in the observation group after treatment was 91.67 %, and the total improvement rate in weight change was 93.75 %, which were significantly higher than those in the control group (62.50 %, 66.67 %, P<0.05). The TCM symptom score of the two groups after treatment were significantly lower than before treatment (P<0.05), and the observation group was significantly lower than the control group (P<0.05). The total effective rate of the observation group was 83.33 %, significantly higher than the control group (45.83 %, P<0.05). After treatment, the CD3+ and CD4+ cell counts and CD4+/CD8+ values in the peripheral blood T lymphocyte subsets of the two groups were significantly higher than before treatment (P<0.05), and the above indicators in the observation group were significantly higher than the control group (P<0.05), although the CD8+ cell count in T lymphocyte subsets was slightly higher than before treatment, the difference between the groups was not statistically significant (P>0.05). The incidence of neutropenia and nausea and vomiting in the control group was higher than that in the observation group (P<0.05), and there was no difference between the two groups in the incidence of thrombocytopenia and diarrhea (P>0.05). Conclusion: Baofei cream could better control the development of NSCLC, improve the clinical symptoms, improve the immunity, and have no obvious toxic and side effects after long-term use. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
